Ketamine Education
Ketamine vs. Spravato: Understanding the Differences
Ketamine and Spravato are related medications, but they are not interchangeable. Learn how they differ in FDA approval, administration, safety, and treatment considerations.
People exploring additional treatment options for depression may encounter two terms that sound closely related: ketamine and Spravato.
Both have been discussed in connection with depression treatment, especially when conventional antidepressants have not provided adequate improvement.
Because these medications are chemically related, it can be easy to assume they work the same way or have the same medical approvals.
However, there are important differences.
Understanding those differences can help people ask informed questions when discussing potential treatment options with a qualified healthcare professional.
What is ketamine?
Ketamine is a prescription medication that has been used in medical settings for decades.
The FDA has approved ketamine products for specific anesthetic uses, including certain procedures requiring general anesthesia.
Ketamine affects the brain's N-methyl-D-aspartate (NMDA) receptor system, which is involved in glutamate signaling.
Researchers have studied ketamine's potential effects on depressive symptoms, particularly in individuals experiencing treatment-resistant depression.
Some clinicians prescribe ketamine off-label for certain psychiatric conditions.
Off-label use means that a medication is being prescribed for a purpose that is not included in its FDA-approved indications.
Off-label prescribing can occur in legitimate medical practice, but it does not mean the FDA has approved the medication for that condition.
Ketamine itself is not FDA-approved for treating depression, PTSD, anxiety, or other psychiatric disorders.
What is Spravato?
Spravato is the brand name for esketamine, a prescription nasal spray.
Esketamine is chemically related to ketamine. Ketamine contains two mirror-image molecular forms, while esketamine is one of those forms.
Spravato has FDA-approved indications for:
- Treatment-resistant depression in adults, either as monotherapy or in conjunction with an oral antidepressant.
- Depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, in conjunction with an oral antidepressant.
The second indication has important limitations. Spravato has not been demonstrated to prevent suicide or reduce suicidal ideation or behavior, and it does not replace hospitalization when hospitalization is clinically necessary.
Spravato must be administered in a certified healthcare setting under the supervision of healthcare professionals.
It is not a medication that patients take home for unsupervised administration.
What are the biggest differences between ketamine and Spravato?
Although both medications are related, they differ in regulatory approval, formulation, administration, and clinical requirements.
FDA approval
Ketamine is FDA-approved for anesthetic uses, not psychiatric disorders.
Spravato is FDA-approved for specific depressive indications in adults.
This is one of the most important distinctions for patients to understand.
Formulation
Ketamine products used in clinical practice may involve different formulations and routes of administration, depending on the medical indication and treatment setting.
Spravato is a specifically approved esketamine nasal spray.
The two products are not interchangeable.
Administration
FDA-approved ketamine anesthesia products are administered by injection.
When ketamine is used off-label in psychiatric care, the route and protocol depend on the treating clinician and clinical setting. Some formulations may be compounded, which introduces additional considerations because compounded products are not FDA-approved.
Spravato is administered intranasally under direct professional supervision in a certified healthcare setting.
Monitoring
Ketamine can affect blood pressure, breathing, perception, alertness, and other functions. Appropriate safety precautions and monitoring depend on the formulation, route, dose, and clinical circumstances.
Spravato has specific FDA-mandated administration and monitoring requirements, including observation for at least two hours after each treatment session.
Treatment eligibility
Neither medication should be treated as a consumer product that anyone can select without assessment.
A qualified clinician must evaluate diagnosis, prior treatment response, medical history, possible contraindications, other medications, and treatment risks.
Ketamine vs. Spravato at a glance
| Consideration | Ketamine | Spravato |
|---|---|---|
| Medication | Ketamine | Esketamine |
| FDA approval | Anesthetic uses | Specific adult depression indications |
| Psychiatric use | Off-label | FDA-approved for specified indications |
| Formulation | Varies by product and use | Prescription nasal spray |
| Administration | Depends on indication and protocol | Supervised nasal administration |
| Monitoring | Depends on treatment and clinical risks | At least two hours of supervised monitoring |
| Treatment decision | Individual clinical assessment | Individual clinical assessment and REMS requirements |
How does Spravato treatment work?
Spravato is provided through the SPRAVATO Risk Evaluation and Mitigation Strategy, commonly called the REMS program.
This restricted program is designed to address significant safety concerns associated with the medication.
A treatment session generally involves:
Before administration
Healthcare professionals review relevant clinical information, assess whether treatment remains appropriate, and evaluate blood pressure and other safety considerations.
During administration
The patient self-administers the nasal spray under the direct supervision of a healthcare professional.
The healthcare team follows the approved administration and monitoring procedures.
After administration
The patient is monitored for at least two hours.
Monitoring includes assessment for changes in blood pressure, breathing, alertness, and other clinically significant effects.
The healthcare provider determines when the patient is stable and ready to leave.
After leaving the facility
Patients must arrange transportation home and should not drive or operate machinery until the next day after a restful sleep, consistent with prescribing instructions.
A treating clinician explains the specific treatment schedule and any additional precautions.
What safety considerations should patients understand?
Both medications require careful medical consideration.
Ketamine considerations
Potential concerns associated with ketamine may include:
- Increases in blood pressure or heart rate.
- Changes in perception or dissociation.
- Sedation or impaired alertness.
- Respiratory complications.
- Nausea or other adverse effects.
- Risks associated with misuse or repeated exposure.
Safety considerations vary depending on administration method, dose, frequency, and individual health circumstances.
The FDA has also warned about risks associated with compounded ketamine products for psychiatric use, particularly when treatment occurs without adequate healthcare supervision.
Spravato considerations
Spravato carries boxed warnings addressing significant risks including sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors associated with antidepressant treatment in younger patients.
Spravato can also cause increases in blood pressure.
Because of these risks, treatment requires specific screening, administration, and monitoring procedures.
Patients should discuss their medical history and potential contraindications with their healthcare professional.
Is one treatment more effective than the other?
It is not appropriate to assume that one medication is universally more effective or safer for every patient.
Clinical studies have evaluated ketamine and esketamine in different populations and treatment settings.
Differences in study design, dose, administration methods, and patient characteristics make simple comparisons difficult.
The evidence supporting a particular treatment must be interpreted within the context of an individual's diagnosis and clinical circumstances.
The most suitable choice, if either is appropriate, requires professional evaluation.
Are ketamine and Spravato treatments for PTSD or anxiety?
Neither ketamine nor Spravato is FDA-approved specifically for PTSD or anxiety disorders.
Although research has explored ketamine in additional psychiatric conditions, investigational findings should not be confused with established FDA-approved indications.
Patients experiencing PTSD, anxiety, or trauma-related concerns should discuss evidence-based treatment options with qualified clinicians.
When depression occurs alongside another mental-health condition, each diagnosis and its treatment needs should be considered.
Does Spravato replace regular psychiatric care?
Not necessarily.
Depending on the individual's circumstances, mental-health treatment may involve psychiatric follow-up, medication management, psychotherapy, and other care approaches.
Spravato is administered according to its approved indications and clinical requirements.
A qualified clinician determines how it fits into an overall care plan.
What should patients ask before considering either treatment?
Useful questions include:
- What diagnosis is being treated?
- Have my previous treatments been adequately evaluated?
- What evidence supports this treatment for my condition?
- Is the proposed use FDA-approved or off-label?
- What are the potential benefits and limitations?
- What side effects or safety risks should I understand?
- What type of monitoring is required?
- How will response to treatment be assessed?
- What are the costs and possible insurance considerations?
- What other treatment options should be discussed?
A thoughtful conversation should include both potential benefits and potential risks.
Choosing an appropriate next step
Ketamine and Spravato represent different medical approaches with distinct regulatory and safety considerations.
Understanding those distinctions matters, especially for adults whose depression has not responded adequately to previous treatment.
The next step isn't necessarily choosing a medication.
It may be obtaining a comprehensive psychiatric evaluation to review the diagnosis, prior treatment attempts, overall health, and options worth considering.
At Neurobody Wellness Center, treatment planning begins with understanding the individual and determining which available care pathways may be appropriate.
Have questions about advanced depression-treatment options?
A psychiatric evaluation can help clarify whether additional treatment approaches deserve consideration.
Request an Evaluation · Learn About Spravato
Frequently Asked Questions
Are ketamine and Spravato the same drug?
No. Ketamine and esketamine are chemically related, but they are distinct medications with different formulations, approvals, and clinical requirements.
Is Spravato FDA-approved for treatment-resistant depression?
Yes. Spravato is FDA-approved for treatment-resistant depression in adults, either alone or with an oral antidepressant.
Is ketamine FDA-approved for treating depression?
No. Ketamine itself is approved for anesthetic uses. Its psychiatric use for depression is off-label.
Can patients take Spravato at home?
No. Spravato must be administered under supervision in a certified healthcare setting and requires post-treatment monitoring.
How long do patients stay after a Spravato treatment?
The prescribing information requires monitoring for at least two hours after administration, with the healthcare provider determining when the patient is clinically stable and ready to leave.
Is Spravato approved to prevent suicide?
No. Its effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated.
Does insurance cover ketamine or Spravato?
Coverage depends on the insurer, the policy, the indication, the treatment, and other requirements. Patients should confirm current coverage and eligibility with their insurer and care team.
How can someone find out whether either treatment may be appropriate?
A qualified clinician can assess the diagnosis, previous treatments, medical history, safety considerations, and available options.
Related Reading
- Ketamine Therapy
- Spravato Treatment
- What Is Treatment-Resistant Depression?
- Depression & Treatment-Resistant Depression
- Psychiatric Evaluations
Sources
This article is intended for general educational purposes and does not replace personalized medical advice, diagnosis, or treatment. Treatment decisions should be made in consultation with qualified healthcare professionals. If you are in crisis, call or text 988 or dial 911.
